期刊文献+

Hypertrophic cardiomyopathy and sudden cardiac death 被引量:1

Hypertrophic cardiomyopathy and sudden cardiac death
下载PDF
导出
摘要 Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disease that affects the left ventricle. HCM can appear at any age, with the majority of the patients remaining clinically stable. When patients complain of symptoms, these include: dyspnea, dizziness, syncope and angina. HCM can lead to sudden cardiac death (SCD), mainly due to ventricular tachyarrhythmia or ventricular tachycardia. High-risk patients benefit from implantable cardioverter-defibrillators. Left ventricular outflow tract obstruction is not a rare feature in HCM, especially in symptomatic patients, and procedures that abolish that obstruction provide positive and consistent results that can improve longterm survival. HCM is the most common cause of sudden death in young competitive athletes and preparticipation screening programs have to be implemented to avoid these tragic fatalities. The structure of these programs is a matter of large debate. Worldwide registries are necessary to identify the full extent of HCMrelated SCD. Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disease that affects the left ventricle. HCM can appear at any age, with the majority of the patients remaining clinically stable. When patients complain of symptoms, these include: dyspnea, dizziness, syncope and angina. HCM can lead to sudden cardiac death (SCD), mainly due to ventricular tachyarrhythmia or ventricular tachycardia. High-risk patients benefit from implantable cardioverter-defibrillators. Left ventricular outflow tract obstruction is not a rare feature in HCM, especially in symptomatic patients, and procedures that abolish that obstruction provide positive and consistent results that can improve long-term survival. HCM is the most common cause of sudden death in young competitive athletes and preparticipation screening programs have to be implemented to avoid these tragic fatalities. The structure of these programs is a matter of large debate. Worldwide registries are necessary to identify the full extent of HCM-related SCD.
出处 《World Journal of Cardiology》 CAS 2010年第9期289-298,共10页 世界心脏病学杂志(英文版)(电子版)
关键词 HYPERTROPHIC CARDIOMYOPATHY GENETICS Management Risk-stratification ATHLETES SUDDEN cardiac death Hypertrophic cardiomyopathy Genetics Management Risk-stratification Athletes Sudden cardiac death
  • 相关文献

参考文献108

  • 1Mariusz Klopotowski,Lidia Chojnowska,Lukasz A. Malek,Renata Maczynska,Krzysztof Kukula,Marcin Demkow,Adam Witkowski,Maciej Dabrowski,Maciej Karcz,Rafal Baranowski,Beata Kusmierczyk-Droszcz,Mariusz Kruk,Jacek Jamiolkowski,Mariusz Kusmierczyk,Lukasz Szumowski,Witold Ruzyllo.The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy[J]. Clinical Research in Cardiology . 2010 (5)
  • 2Elijah R. Behr,Perry Elliott,William J. McKenna.Role of Invasive EP Testing in the Evaluation and Management of Hypertrophic Cardiomyopathy[J]. Cardiac Electrophysiology Review . 2002 (4)
  • 3Eiji Takagi,Tetsu Yamakado.Prognosis of Patients with Hypertrophic Cardiomyopathy in Japan[J]. Cardiac Electrophysiology Review . 2002 (1-2)
  • 4di Gioia CR,Autore C,Romeo DM,Ciallella C,Aromatario MR,Lopez A,Pagannone E,Giordano C,Gallo P,d‘Amati G.Sudden cardiac death in younger adults: autopsy diagnosis as a tool for preventive medicine. Human Pathology . 2006
  • 5Jóna I,Nánási PP.Cardiomyopathies and sudden cardiacdeath caused by RyR2 mutations: are the channels the begin- ning and the end?. Cardiovascular Research . 2006
  • 6Fernandes VL,Nielsen C,Nagueh SF,Herrin AE,Slifka C,Franklin J,Spencer WH 3rd.Follow-up of alcohol septal abla- tion for symptomatic hypertrophic obstructive cardiomyopa- thy the Baylor and Medical University of South Carolina ex- perience 1996 to 2007. JACC Cardiovasc Interv . 2008
  • 7Cuoco FA,Spencer WH 3rd,Fernandes VL,Nielsen CD,Nagueh S,Sturdivant JL,Leman RB,Wharton JM,Gold MR.Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. Journal of the American College of Cardiology . 2008
  • 8Ommen SR,Maron BJ,Olivotto I,Maron MS,Cecchi F,Be- tocchi S,Gersh BJ,Ackerman MJ,McCully RB,Dearani JA,Schaff HV,Danielson GK,Tajik AJ,Nishimura RA.Long- term effects of surgical septal myectomy on survival in pa- tients with obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology . 2005
  • 9Woo A,Williams WG,Choi R,Wigle ED,Rozenblyum E,Fedwick K,Siu S,Ralph-Edwards A,Rakowski H.Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardio- myopathy. Circulation . 2005
  • 10McLeod CJ,Ommen SR,Ackerman MJ,Weivoda PL,Shen WK,Dearani JA,Schaff HV,Tajik AJ,Gersh BJ.Surgical sep- tal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertro- phic cardiomyopathy. European Heart Journal . 2007

共引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部